Kontafarma China Holdings (HKSE:01312) EPS (Basic): HK$-0.08 (TTM As of Dec. 2025)


What is Kontafarma China Holdings EPS (Basic)?

Kontafarma China Holdings HKSE:01312 -3.45% EPS (Basic) is HK$-0.08 as of Dec. 2025. The stock has 3 warning signs investors should review.

Kontafarma China Holdings's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.08.

Kontafarma China Holdings's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.08.

Kontafarma China Holdings's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.06.

During the past 3 years, the average EPS without NRI Growth Rate was -56.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Kontafarma China Holdings's highest 3-Year average EPS without NRI Growth Rate was 22.90% per year. The lowest was -60.20% per year. And the median was -38.75% per year.

Kontafarma China Holdings  (HKSE:01312) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Kontafarma China Holdings EPS (Basic) Related Terms

Kontafarma China Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Kontafarma China Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings EPS (Basic) Chart

Kontafarma China Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.01 -0.01 -0.01 -0.08

Kontafarma China Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 -0.01 -0.05 -0.03

Kontafarma China Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Kontafarma China Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-427.848-0)/5578.714
=-0.08

Kontafarma China Holdings's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-145.364-0)/5578.714
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.08 mean?
Kontafarma China Holdings (HKSE:01312) has a EPS (Basic) of HK$-0.08 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Kontafarma China Holdings and its competitors.
Is Kontafarma China Holdings' EPS (Basic) too high?
Kontafarma China Holdings' current EPS (Basic) is HK$-0.08.
How does Kontafarma China Holdings' EPS (Basic) compare to ZTS?
Kontafarma China Holdings' EPS (Basic) of HK$-0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Kontafarma China Holdings and its competitors. Kontafarma China Holdings's current EPS (Basic) is HK$-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 30% below its estimated fair value. The current EPS (Basic) is HK$-0.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current EPS (Basic) is HK$-0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kontafarma China Holdings Business Description

Address 30 Harbour Road, Room 12A15-12A20, 12A Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.